CXCR2-expressing CAR-T cells against the integrin αvβ6 can migrate more efficiently towards tumor-conditioned media containing IL-8 and exhibit superior antitumor activity against established αvβ6-expressing ovarian or pancreatic tumor xenografts, with a more favorable toxicity profile [34]. This evidence concerns the gene CXCL8 and neoplasm.